Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Theratechnologies Inc (NQ: THTX ) 1.455 +0.010 (+0.69%) Streaming Delayed Price Updated: 3:59 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Theratechnologies Inc < Previous 1 2 3 4 5 Next > AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know October 02, 2022 Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... Via Benzinga Stocks That Hit 52-Week Lows On Wednesday August 10, 2022 During Wednesday, 52 stocks hit new 52-week lows. Via Benzinga Theratechnologies Stock Jumps After Q2 Earnings, FY22 Guidance July 14, 2022 Via Benzinga Recap: Theratechnologies Q2 Earnings July 14, 2022 Theratechnologies (NASDAQ:THTX) reported its Q2 earnings results on Thursday, July 14, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement July 27, 2022 This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14,... From Theratechnologies Via GlobeNewswire The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures July 14, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Earnings Scheduled For July 14, 2022 July 14, 2022 Companies Reporting Before The Bell • Telefonaktiebolaget L M (NASDAQ:ERIC) is expected to report quarterly earnings at $0.16 per share on revenue of $6.45 billion. Via Benzinga A Preview Of Theratechnologies's Earnings July 13, 2022 Theratechnologies (NASDAQ:THTX) is set to give its latest quarterly earnings report on Thursday, 2022-07-14. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga Stocks That Hit 52-Week Lows On Thursday July 07, 2022 Thursday's session saw 49 companies set new 52-week lows. Via Benzinga The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More April 13, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal Via Benzinga Theratechnologies Earnings Preview April 12, 2022 Theratechnologies (NASDAQ:THTX) is set to give its latest quarterly earnings report on Wednesday, 2022-04-13. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More April 10, 2022 Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. Via Benzinga Theratechnologies Q1 2022 Earnings Conference Call On April 13, 2022 At 08:30 AM ET April 01, 2022 Theratechnologies (NASDAQ:THTX) will host a conference call at 08:30 AM ET on April 13, 2022, to discuss Q1 2022 earnings results. Via Benzinga Theratechnologies Q3 Earnings Lags Consensus As Trogarzo Sales Decline October 13, 2021 Theratechnologies Inc (NASDAQ: THTX) reported Q3 sales of $17.85 million, +27% Y/Y propelled by higher Egrifta sales of $11.22 million, +64%. The revenue missed... Via Benzinga The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal October 13, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... Via Benzinga Exposures Product Safety Earnings Scheduled For October 13, 2021 October 13, 2021 Companies Reporting Before The Bell • BlackRock (NYSE:BLK) is estimated to report quarterly earnings at $9.23 per share on revenue of $4.81 billion. • Delta Air... Via Benzinga The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage October 10, 2021 Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... Via Benzinga Exposures Product Safety The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More October 03, 2021 Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... Via Benzinga Exposures Product Safety Theratechnologies' IV Push Form Of HIV Treatment At Par With IV Infusion September 22, 2021 Theratechnologies Inc (NASDAQ: THTX) has announced results from a study evaluating an intravenous (IV) push form of Trogarzo (ibalizumab-uiyk) for HIV-1 infection... Via Benzinga 10 Biggest Price Target Changes For Thursday July 29, 2021 Canaccord Genuity cut Theratechnologies Inc. (NASDAQ: THTX) price target from $8 to $3. Theratechnologies shares gained 4.5% to close at $3.71 on Wednesday. Guggenheim lifted... Via Benzinga Theratechnologies In Search Of Potential Partner For Late-Stage NASH Study Of Tesamorelin, Reports Q2 Earnings July 15, 2021 Theratechnologies Inc (NASDAQ: THTX) has completed discussions with the FDA and European Medicines Agency regarding its proposed trial design and protocol for its... Via Benzinga Exposures Product Safety The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs July 15, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,... Via Benzinga Topics Product Recall Exposures Legal Product Safety Earnings Scheduled For July 15, 2021 July 15, 2021 Companies Reporting Before The Bell • Truist Financial (NYSE:TFC) is estimated to report quarterly earnings at $1.17 per share on revenue of $5.47 billion. •... Via Benzinga Theratechnologies Peptide-Drug Conjugate Shows Better Anti-Metastatic Activity Compared With Docetaxel Alone June 21, 2021 Theratechnologies Inc (NASDAQ: THTX) has announced new preclinical in vivo findings on its peptide-drug conjugate (PDC), TH1902. The results demonstrate that... Via Benzinga The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight April 10, 2021 Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... Via Benzinga Exposures Product Safety The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead April 14, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (... Via Benzinga Exposures Product Safety Stocks That Hit 52-Week Highs On Tuesday April 13, 2021 This morning 106 companies set new 52-week highs. Interesting Highlights: Microsoft (NASDAQ:MSFT) was the largest company by market cap to set a new 52-week high... Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.